Switching to aripiprazole as a strategy for weight reduction: A meta-analysis in patients suffering from schizophrenia

Journal of Obesity

Volumn 2011, Issue , 2011, Pages

  Barak, Yoram ^a   Aizenberg, Dov ^a  

^a ABARBANEL MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84861965526     PISSN: 20900708     EISSN: 20900716     Source Type: Journal    
DOI: 10.1155/2011/898013     Document Type: Article

References (28)

1. Faulkner G., Cohn T., Remington G., Interventions to reduce weight gain in schizophrenia. Cochrane Database of Systematic Reviews 2007 1 CD005148 2-s2.0-34247847846
2. Nasrallah H. A., Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrums 2006 11 7, supplement 7 32 39 2-s2.0-33746541024 (Pubitemid 44141227)
3. Baptista T., ElFakih Y., Uzcátegui E., Sandia I., Tálamo E., Araujo De Baptista E., Beaulieu S., Pharmacological management of atypical antipsychotic-induced weight gain. CNS Drugs 2008 22 6 477 495 2-s2.0-43749104014 10.2165/00023210-200822060-00003 (Pubitemid 351693690)
4. Buchanan R. W., rwbuchanan@mprc.umaryland.edu Kreyenbuhl J., Kelly D. L., Noel J. M., Boggs D. L., Fischer B. A., Himelhoch S., Fang B., Peterson E., Aquino P. R., Keller W., The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 2010 36 1 71 93 2-s2.0-0031904437 10.1093/schbul/sbp116
5. Weber M., Gutierrez A. M., Mohammadi M., The risks and benefits of switching antipsychotics: a case study approach. Perspectives in Psychiatric Care 2009 45 1 54 61 2-s2.0-58149350279 10.1111/j.1744-6163.2009.00200.x
6. Brixner D. I., Said Q., Corey-Lisle P. K., Tuomari A. V., L'Italien G. J., Stockdale W., Oderda G. M., Naturalistic impact of second-generation antipsychotics on weight gain. Annals of Pharmacotherapy 2006 40 4 626 632 2-s2.0-33646252502 10.1345/aph.1G564
7. Gentile S., A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole. Neuropsychiatric Disease and Treatment 2009 5 1 117 125 2-s2.0-70449722920
8. Pae C.-U., A review of the safety and tolerability of aripiprazole. Expert Opinion on Drug Safety 2009 8 3 373 386 2-s2.0-67649322211 10.1517/14740330902835493
9. Komossa K., Rummel-Kluge C., Schmid F., Hunger H., Schwarz S., El-Sayeh H.G., Kissling W., Leucht S., Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009 4 CD006569
10. Downs S. H., Black N., The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology and Community Health 1998 52 6 377 384 2-s2.0-0031754739 (Pubitemid 28438523)
11. Pigott T. A., Carson W. H., Saha A. R., Torbeyns A. F., Stock E. G., Ingenito G. G., Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. Journal of Clinical Psychiatry 2003 64 9 1048 1056 2-s2.0-0141828595 (Pubitemid 37158250)
12. Casey D. E., Carson W. H., Saha A. R., Liebeskind A., Ali M. W., Jody D., Ingenito G. G., Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology 2003 166 4 391 399 2-s2.0-0037393107 (Pubitemid 36469941)
13. Chavez B., Poveda R. A., Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances. Annals of Pharmacotherapy 2006 40 12 2265 2268 2-s2.0-33845631220 10.1345/aph.1H240 (Pubitemid 44954452)
14. Lin S.-K., Chen C.-K., Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report. Journal of Clinical Psychiatry 2006 67 8 1307 2-s2.0-33748964966 (Pubitemid 44439707)
15. Spurling R. D., Lamberti J. S., Olsen D., Tu X., Tang W., Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. Journal of Clinical Psychiatry 2007 68 3 406 409 2-s2.0-33947713749 (Pubitemid 46506805)
16. Kim S. H., Ivanova O., Abbasi F. A., Lamendola C. A., Reaven G. M., Glick I. D., Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. Journal of Clinical Psychopharmacology 2007 27 4 365 368 2-s2.0-34447521690 10.1097/JCP.0b013e3180a9076c (Pubitemid 47075507)
17. Schorr S. G., Slooff C. J., Postema R., Van Oven W., Schilthuis M., Bruggeman R., Taxis K., A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole. Acta Psychiatrica Scandinavica 2008 118 3 246 250 2-s2.0-48749106212 10.1111/j.1600-0447.2008.01232.x
18. Newcomer J. W., Campos J. A., Marcus R. N., Breder C., Berman R. M., Kerselaers W., L'Italien G. J., Nys M., Carson W. H., McQuade R. D., A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. Journal of Clinical Psychiatry 2008 69 7 1046 1056 2-s2.0-47749138165 (Pubitemid 352031586)
19. Pae C.-U., Serretti A., Chiesa A., Mandelli L., Lee C., Lee C., Kim J., De Ronchi D., Paik I.-H., Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. European Neuropsychopharmacology 2009 19 8 562 570 2-s2.0-67549130165 10.1016/j.euroneuro.2009.04.002
20. Kim S.-W., Shin I.-S., Kim J.-M., Lee J.-H., Lee Y.-H., Yang S.-J., Yoon J.-S., Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clinical Neuropharmacology 2009 32 5 243 249 2-s2.0-70349811302 10.1097/WNF.0b013e31819a68b5
21. Takeuchi H., hirotak@dk9.so-net.ne.jp Uchida H., Suzuki T., Watanabe K., Kashima H., Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study. Psychiatry and Clinical Neurosciences 2010 64 1 104 106 2-s2.0-40549118840 10.1111/j.1440-1819.2009.02036.x
22. Lambert T. J. R., Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder. Evidence-Based Mental Health 2009 12 2 50 2-s2.0-67449149624 10.1136/ebmh.12.2.50
23. Kane J. M., Osuntokun O., Kryzhanovskaya L. A., Xu W., Stauffer V. L., Watson S. B., Breier A., A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Journal of Clinical Psychiatry 2009 70 4 572 581 2-s2.0-65449123582 10.4088/JCP.08m04421
24. Tandon R., Marcus R. N., Stock E. G., Riera L. C., Kostic D., Pans M., McQuade R. D., Nyilas M., Iwamoto T., Crandall D. T., A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophrenia Research 2006 84 1 77 89 2-s2.0-33747481325 10.1016/j.schres.2005.12.857 (Pubitemid 44255718)
25. Wolf J., Janssen F., Lublin H., Salokangas R. K. R., Allain H., Smeraldi E., Bernardo M., Millar H., Pans M., Adelbrecht C., Laughton J., Werner C., Maier W., A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Current Medical Research and Opinion 2007 23 10 2313 2323 2-s2.0-35648970593 10.1185/030079907X225448 (Pubitemid 350033433)
26. Deberdt W., Winokur A., Cavazzoni P. A., Trzaskoma Q. N., Carlson C. D., Bymaster F. P., Wiener K., Floris M., Breier A., Amantadine for weight gain associated with olanzapine treatment. European Neuropsychopharmacology 2005 15 1 13 21 2-s2.0-9644308090 10.1016/j.euroneuro.2004.03.005 (Pubitemid 39574395)
27. Kim C. Y., Chung S., Lee J.-N., Kwon J. S., Kim D. H., Kim C. E., Jeong B., Jeon Y.-W., Lee M.-S., Jun T.-Y., Jung H.-Y., A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology 2009 24 4 181 188 2-s2.0-67651236733 10.1097/YIC. 0b013e32832c25d7
28. Weiden P. J., Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. Journal of Clinical Psychiatry 2007 68 supplement 4 34 39 2-s2.0-34248575535 (Pubitemid 46762121)